NCT00348400View on ClinicalTrials.gov

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

PHASE4CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Glaucoma

Interventions

DRUG

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost

Trial Locations (1)

15213

Dr. Noecker, Pittsburgh

Sponsors

Lead Sponsor

Innovative Medical

All Listed Sponsors

lead

Innovative Medical

INDUSTRY

NCT00348400 - Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost | Biotech Hunter | Biotech Hunter